Obatoclax

Mechanism of action

Obatoclax is an inhibitor of the Bcl-2 family of proteins. This inhibition induces apoptosis in cancer cells, preventing tumor growth. Solubility has been an issue in the development of the drug.

Clinical trials

Clinical trial results have been published for treatment of acute myeloid leukemia, small cell lung cancer, Hodgkin's lymphoma, and myelodysplastic syndromes.

Teva halted a phase III trial in patients with lung cancer before it had begun, citing "business decisions" as the reason.

References

References

1. [http://www.prnewswire.com/news-releases/cephalon-announces-definitive-agreement-to-acquire-gemin-x-118386434.html Cephalon Announces Definitive Agreement to Acquire Gemin X], March 21, 2011
2. (2010). "Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients with Myelofibrosis". Clinical Lymphoma, Myeloma & Leukemia.
3. [https://www.drugs.com/clinical_trials/gemin-x-presents-new-data-obatoclax-american-society-hematology-meeting-6469.html Gemin X Presents New Data on Obatoclax at the American Society of Hematology Meeting], Dec 9, 2008
4. [http://clinicaltrials.gov/search/intervention=Obatoclax Obatoclax] at [[ClinicalTrials.gov]]
5. (2008). "Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)". Cancer Research.
6. (2015). "Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim". BMC Cancer.
7. (2014). "A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia". PLOS ONE.
8. (2014). "Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer". Lung Cancer.
9. (2012). "Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma". Blood.
10. (2014). "A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients with Previously Untreated Myelodysplastic Syndromes with Anemia or Thrombocytopenia". Clinical Lymphoma, Myeloma & Leukemia.
11. {{ClinicalTrialsGov. NCT01563601. Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer